Elranatamab

• Elranatamab Post Trial Access Study for Participants With Multiple Myeloma Pending
  2023-505200-33-00 Phase III 3 countries Pfizer Inc.
• A multi-center, open-label, phase 2 study of Elranatamab in patients with high-risk smoldering multiple myeloma Recruiting
  2023-505775-70-00 Phase II 6 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
• Discontinuation Outcome in Multiple Myeloma after BCMA-CD3 treatment Recruiting
  2025-524022-18-00 Phase II 1 country Vaestra Goetalandsregionen
• Phase 1b/2a Study to Evaluate Mezigdomide in Combination with Elranatamab in Relapsed and/or Refractory Multiple Myeloma Recruiting
  2025-522090-11-00 Phase I/II 4 countries Celgene Corp.
• A phase 3, open-label, controlled, randomized study of newly diagnosed multiple myeloma treatment, designed to evaluate the efficacy and saf… Recruiting
  2024-516418-39-00 Phase III 1 country Intergroupe Francophone Du Myelome
• IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as p… Recruiting
  2024-517325-43-00 Phase II 1 country Centre Hospitalier Universitaire De Nantes
• A first time in man study to look at the safety of the experimental drug CCS1477 and what effects it has on cancers that affect the blood, b… Recruiting
  2024-519498-20-00 Phase I/II 1 country Cellcentric Limited
• Self-administration of subcutaneous Elranatamab in the patients’ homes (ERICA) Recruiting
  2023-507876-30-00 Phase II 1 country Odense University Hospital
• A trial to learn if AZD0305 alone and in combination with other cancer treatments is safe and works in adults with multiple myeloma Recruiting
  2023-508590-89-00 Phase I (FiH) 3 countries AstraZeneca AB
• C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL… Recruiting
  2023-507871-23-00 Phase III 16 countries Pfizer Inc.
• MagnetisMM-6: A Phase 3 Study of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dex… Recruiting
  2024-514139-50-00 Phase III 12 countries Pfizer Inc.
• An open label, multicenter, phase II study of Elranatamab as single agent for the treatment of relapsed or refractory myeloma in patients pr… Ended
  2023-504273-21-00 Phase II 1 country Pethema Fundacion
• A Phase 3 Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant Ended
  2023-508897-27-00 Phase III 14 countries Pfizer Inc.
• MagnetisMM-5: A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dex… Ended
  2023-509208-14-00 Phase III 13 countries Pfizer Inc.
• A Phase 2 Study of Elranatamab (PF-06863135) Monotherapy in Participants With MM Who Are Refractory to at Least One PI, One IMiD and One Ant… Ended
  2023-504479-25-00 Phase II 5 countries Pfizer Inc.

Showing 1–15 of 15 trials